Stay updated on Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial
Sign up to get notified when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.

Latest updates to the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov site revision changed from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedAn NIH-wide notice explains the transition from “Artificial Intelligence” to “Super Intelligence” terminology. The site revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference1.0%

- Check43 days agoChange DetectedThe footer’s ClinicalTrials.gov revision number changes from v3.7.0 to v3.7.1.SummaryDifference0.1%

- Check63 days agoChange DetectedA new revision entry 'Revision: v3.7.0' is added to the study record history, updating the version history. The previous revision 'Revision: v3.6.6' is removed from the current view.SummaryDifference0.1%

- Check77 days agoChange DetectedA new revision entry v3.6.6 was added to the study record history, and the previous revision v3.6.5 was removed from the history.SummaryDifference0.1%

- Check99 days agoChange DetectedThe record history now lists a new revision (v3.6.5) that supersedes the previous version (v3.6.4).SummaryDifference0.1%

Stay in the know with updates to Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pyrotinib Maleate in HER2-Positive Solid Tumors Clinical Trial page.